Literature DB >> 17061997

Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation.

R Watson1, T Kozlowski, V Nickeleit, J T Woosley, J L Schmitz, S L Zacks, J H Fair, D A Gerber, K A Andreoni.   

Abstract

Antibody-mediated rejection (AMR) after liver transplantation is recognized in ABO incompatible and xeno-transplantation, but its role after ABO compatible liver transplantation is controversial. We report a case of ABO compatible liver transplantation that demonstrated clinical, serological and histological signs of AMR without evidence of concurrent acute cellular rejection. AMR with persistently high titers of circulating donor specific antibodies resulted in graft injury with initial centrilobular hepatocyte necrosis, fibroedematous portal expansion mimicking biliary tract outflow obstruction, ultimately resulting in extensive bridging fibrosis. Immunofluorescence microscopy demonstrated persistent, diffuse linear C4d deposits along sinusoids and central veins. Despite intense therapeutic intervention including plasmapheresis, IVIG and rituximab, AMR led to graft failure. We present evidence that an antibody-mediated alloresponse to an ABO compatible liver graft can cause significant graft injury independent of acute cellular rejection. AMR shows distinct histologic changes including a characteristic staining profile for C4d.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17061997     DOI: 10.1111/j.1600-6143.2006.01554.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  15 in total

1.  Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation.

Authors:  Julio Pascual; Milagros D Samaniego; José R Torrealba; Jon S Odorico; Arjang Djamali; Yolanda T Becker; Barbara Voss; Glen E Leverson; Stuart J Knechtle; Hans W Sollinger; John D Pirsch
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

2.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

Review 3.  The role of B cells in solid organ transplantation.

Authors:  Jean Kwun; Pinar Bulut; Eugenia Kim; Wasim Dar; Byoungchol Oh; Ravi Ruhil; Neal Iwakoshi; Stuart J Knechtle
Journal:  Semin Immunol       Date:  2011-12-01       Impact factor: 11.130

4.  Bortezomib for acute antibody-mediated rejection in liver transplantation.

Authors:  F Paterno; M Shiller; G Tillery; J G O'Leary; B Susskind; J Trotter; G B Klintmalm
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

Review 5.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

Review 6.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

7.  Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation.

Authors:  Nassim Kamar; Laurence Lavayssière; Fabrice Muscari; Janick Selves; Céline Guilbeau-Frugier; Isabelle Cardeau; Laure Esposito; Olivier Cointault; Marie Béatrice Nogier; Jean Marie Peron; Philippe Otal; Marylise Fort; Lionel Rostaing
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

Review 8.  Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis.

Authors:  Yu-Gang Zhao; Bing-Yi Shi; Ye-Yong Qian; Hong-Wei Bai; Li Xiao; Xiu-Yun He
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

9.  Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume.

Authors:  Geun Hong; Nam-Joon Yi; Suk-won Suh; Tae Yoo; Hyeyoung Kim; Min-Su Park; YoungRok Choi; Kyungbun Lee; Kwang-Woong Lee; Myoung Hee Park; Kyung-Suk Suh
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

10.  Anti-HLA and anti-MICA antibodies in liver transplant recipients: effect on long-term graft survival.

Authors:  Michał Ciszek; Bartosz Foroncewicz; Krzysztof Mucha; Dorota Żochowska; Bogna Ziarkiewicz-Wróblewska; Marek Krawczyk; Leszek Pączek
Journal:  Clin Dev Immunol       Date:  2013-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.